CF Drug's hidden impact on gut and lung bugs revealed

NCT ID NCT05937815

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tracks 253 cystic fibrosis patients starting a new drug combination (elexacaftor/tezacaftor/ivacaftor). Researchers collect sputum, stool, and blood samples at the start, 6 months, and 1 year to see how the drug changes bacteria and inflammation in the lungs and gut. The goal is to understand the drug's full effects beyond just breathing.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Elexacaftor/Tezacaftor/Ivacaftor
What this could lead to
If successful, this could reveal how the drug improves gut and lung health in cystic fibrosis, guiding better future treatments.
What could go wrong
This is an observational study, not a treatment trial. It cannot prove the drug works or is safe, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis Inflammation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • AP-HM CRCM pédiatrique

    RECRUITING

    Marseille, France

  • AP-HP CRCM Robert debré

    RECRUITING

    Paris, France

  • AP-PH Hopital Cochin service de pédiatrie

    RECRUITING

    Paris, France

  • APHP Hopital Necker

    RECRUITING

    Paris, France

  • CHRU de Lille CRCM Pédiatrique

    RECRUITING

    Lille, France

  • CHU de Bordeaux - CRCM pédiatrique

    RECRUITING

    Bordeaux, France

  • CHU de Grenoble Alpes CRCM pédiatrique

    RECRUITING

    Grenoble, France

  • CHU de Limoges CRCM Limousin

    RECRUITING

    Limoges, France

  • CHU de Montpellier

    RECRUITING

    Montpellier, France

  • CHU de Nancy

    RECRUITING

    Nancy, France

  • CHU de Nice

    RECRUITING

    Nice, France

  • CHU de Rouen

    RECRUITING

    Rouen, France

  • CHU de Toulouse

    RECRUITING

    Toulouse, France

  • Fondation Ildys, Roscoff Centre Hélio Marin - Clinique "Mucoviscidose"

    RECRUITING

    Roscoff, France

  • Hospices Civils de Lyon Service de pédiatrie, allergologie et mucoviscidose

    RECRUITING

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.